CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study - 29/08/11
, Thomas B Casale, MD b, Ellen Frankel, MD c, Bernard Goffe, MD d, Nicholas Lowe, MD e, Hans D Ochs, MD f, Janet L Roberts, MD g, Ken Washenik, MD, PhD h, Akshay K Vaishnaw, MD, PhD i, Kenneth B Gordon, MD jAbstract |
Background |
Alefacept, human LFA-3/IgG1 fusion protein, selectively reduces memory-effector (CD45RO+) T cells, a source of the pathogenic mediators of psoriasis.
Objective |
To evaluate the effect of alefacept on immune function, T-cell-dependent humoral responses to a neoantigen (φX174) and recall antigen (tetanus toxoid) were assessed.
Methods |
Patients with psoriasis were randomized to the control group or to receive alefacept (7.5 mg intravenously weekly for 12 weeks). The alefacept group received φX174 immunizations at weeks 6, 12, 20, and 26 and tetanus toxoid at week 21; control subjects received φX174 at weeks 6 and 12 and tetanus at week 10.
Results |
Mean anti-φX174 titers were comparable in both groups. There was no difference in the percentage of responders (anti-φX174 IgG ≥30% of the total anti-φX174) between the alefacept group and the control group (86% and 82%, respectively; P = .73). The percentage of patients with anti-tetanus toxoid titer increases ≥2 times baseline also was similar (alefacept, 89%; control 91%).
Conclusion |
A single 12-week course of alefacept did not impair primary or secondary antibody responses to a neoantigen or memory responses to a recall antigen. The selective immunomodulatory effect of alefacept against a potentially pathogenic T-cell subset is associated with maintenance of a significant aspect of immune function (antibody response) to fight infection and respond to vaccinations.
Le texte complet de cet article est disponible en PDF.Plan
 | Funding sources: Biogen, Inc, Cambridge, Massachusetts. General support for the Clinical Research Center comes from Merck Inc and the David M. C. Ju Foundation. Disclosure: Drs Gottlieb, Washenik, and Gordon are consultants to Biogen, Inc. Dr Vaishnaw is an employee of Biogen, Inc. Drs Casale, Frankel, Goffe, Lowe, Ochs, and Roberts have conducted Biogen funded studies but have no conflict of interest to disclose. |
Vol 49 - N° 5
P. 816-825 - novembre 2003 Retour au numéro
Article précédent
- Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial
- Peter Heald, Marilyn Mehlmauer, Ann G Martin, Constance A Crowley, Richard C Yocum, Steven D Reich, Worldwide Bexarotene Study Group
- Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide
- Russell A. Ball, Tosca Kinchelow, ISR Substudy Group★
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?